| Literature DB >> 28981201 |
Da-Hye Lee1,2, Min Jung Kim1, Jiyun Ahn1,2, Sang Hee Lee1, Hyunjung Lee1, Jin Hee Kim1, So-Hyun Park1,2, Young-Jin Jang1, Tae-Youl Ha1,2, Chang Hwa Jung1,2.
Abstract
SCOPE: Cheonggukjang (CGJ) is a soybean-based quick-fermented food popular in Korea that contains a variety of biologically active compounds including isoflavones and saponins. Isoflavone bioavailability may be important for the bone health of postmenopausal women; therefore, the aim of this study is to evaluate the influence of fermentation on the isoflavone metabolite nutrikinetic profile after single dose CGJ or unfermented soybean administration in ovariectomized (OVX) and sham mice. METHODS ANDEntities:
Keywords: Cheonggukjang; bioavailability; isoflavones; nutrikinetics; ovariectomized mice
Mesh:
Substances:
Year: 2017 PMID: 28981201 PMCID: PMC6139428 DOI: 10.1002/mnfr.201700322
Source DB: PubMed Journal: Mol Nutr Food Res ISSN: 1613-4125 Impact factor: 5.914
Changes in isoflavone compositions of Cheonggukjang (CGJ) during fermentation.
| Isoflavones (μg/g, w/w) | Fermentation time (day) | ||||
|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | ||
| Glycosides | Genistin | 144.53 ± 3.85 | 100.67 ± 10.91 | 27.21 ± 5.82 | 11.95 ± 0.44 |
| Daidzin | 463.29 ± 16.31 | 343.16 ± 59.92 | 57.08 ± 12.25 | 29.54 ± 2.34 | |
| Glycitin | 87.95 ± 1.48 | 69.42 ± 7.33 | 13.89 ± 3.191 | 8.66 ± 0.24 | |
| Acetyl‐ glucosides | Acetylgenistin | 48.66 ± 0.84 | 41.75 ± 6.55 | 11.97 ± 3.00 | 3.50 ± 0.22 |
| Acetyldaidzin | 22.24 ± 0.68 | 17.70 ± 2.80 | 2.76 ± 0.58 | 0.20 ± 0.06 | |
| Acetylglycitin | 5.00 ± 0.19 | 4.30 ± 0.62 | 0.94 ± 0.19 | 0.31 ± 0.00 | |
| Malonyl ‐glucosides | Malonylgenistin | 3.19 ± 0.12 | 2.31 ± 0.29 | 0.71 ± 0.20 | 0.40 ± 0.01 |
| Malonyldaidzin | 0.91 ± 0.03 | 0.71 ± 0.09 | 0.26 ± 0.04 | 0.12 ± 0.01 | |
| Malonylglycitin | 0.25 ± 0.02 | 0.22 ± 0.02 | 0.09 ± 0.01 | 0.05 ± 0.00 | |
| Aglycones | Genistein | 20.55 ± 0.83 | 103.71 ± 16.05 | 318.465 ± 64.73 | 291.41 ± 7.60 |
| Daidzein | 11.90 ± 1.27 | 70.47 ± 7.64 | 193.28 ± 37.71 | 187.57 ± 8.39 | |
| Glycitein | 6.54 ± 0.35 | 27.92 ± 4.37 | 73.46 ± 14.20 | 69.01 ± 2.53 | |
| Others | Formononetin | 0.07 ± 0.00 | 0.13 ± 0.02 | 0.25 ± 0.05 | 0.26 ± 0.00 |
| Dihydrodaidzein | trace | 0..02 ± 0.00 | 0.16 ± 0.03 | 0.17 ± 0.00 | |
| Coumestrol | 0.10 ± 0.01 | 0.14 ± 0.04 | 0.12 ± 0.03 | 0.19 ± 0.03 | |
| Total | 815.18 ± 23.71 | 782.61 ± 113.87 | 700.63 ± 141.20 | 603.36 ± 16.15 | |
Identified isoflavone metabolites from the pooled serum.
| No. | Group of metabolites | Metabolite | RT (min) | Exact mass ( | Actual mass ( | Mass error (mDa) | Annotation level |
|---|---|---|---|---|---|---|---|
| 1 | Intact isoflavone | Genistein | 8.81 | 269.045 | 269.0457 | 0.73 | 1 |
| 2 | Daidzein | 7.44 | 253.0501 | 253.0507 | 0.6 | 1 | |
| 3 | Glycitein | 7.75 | 283.0606 | 283.0606 | 0.03 | 1 | |
| 4 | Phase I metabolites (Liver) | 3‐Hydroxygenistein | 5.02 | 285.0399 | 285.0399 | 0 | 1 |
| 5 | 6‐Hydroxydaidzein | 6.73 | 269.0450 | 269.043 | −2 | 1 | |
| 6 | Phase II metabolites (Liver) | Genistein 4′‐glucuronide | 5.89 | 445.0771 | 445.0771 | 0.02 | 1 |
| 7 | Genistein 7‐glucuronide | 5.34 | 445.0771 | 445.0772 | 0.07 | 1 | |
| 8 | Genistein 4′‐sulfate | 7.19 | 349.0018 | 349.0022 | 0.41 | 1 | |
| 9 | Genistein 7‐sulfate | 5.84 | 349.0018 | 349.002 | 0.2 | 1 | |
| 10 | Daidzein 7‐glucuronide | 4.36 | 429.0822 | 492.0827 | 0.49 | 1 | |
| 11 | Daidzein 4′‐sulfate | 6.12 | 333.0069 | 349.0072 | 0.32 | 1 | |
| 12 | Methylgenistein | 6.25 | 283.0606 | 283.0612 | 0.64 | 1 | |
| 13 | Formononetin | 10.3 | 267.0657 | 267.0667 | 0.99 | 1 | |
| 14 | Gut‐mediated metabolites | Dihydrogenistein | 7.34 | 271.0612 | 271.0606 | −0.60 | 1 |
| 15 | Dihydrogenistein sulfate | 6.99 | 351.0175 | 351.0165 | −0.97 | 1 | |
| 16 | Dihydrodaidzein | 7.5 | 255.0657 | 255.0643 | −1.4 | 1 | |
| 17 | Dihydrodaidzein sulfate | 6.21 | 335.0225 | 335.0227 | 0.17 | 1 | |
| 18 | Equol 7‐glucuronide | 6.16 | 417.1186 | 417.1181 | −0.47 | 1 | |
| 19 | Equol 4′‐sulfate | 2.31 | 321.0426 | 324.0438 | 1.21 | 1 | |
| 20 | 5‐Hydroxy equol | 7.4 | 257.0814 | 257.0800 | −1.4 | 2 | |
| 21 | Hippuric acid | 1.65 | 178.0532 | 178.0513 | −1.90 | 1 | |
| 22 | 4‐Hydroxybenzoic acid | 3.08 | 137.0239 | 137.0252 | 1.26 | 1 | |
| 23 | 2,6‐Dimethoxy benzoic acid | 5.15 | 181.0501 | 181.0517 | 1.56 | 1 | |
| 24 | Caffeic acid | 3.77 | 179.0344 | 179.0356 | 1.16 | 1 | |
| 25 | Methyl caffeic acid | 6.16 | 193.0501 | 193.0515 | 1.41 | 1 | |
| 26 | Fumaric acid | 0.75 | 115.0031 | 115.0046 | 1.53 | 1 | |
| 27 | 4‐Ethylphenol | 9.46 | 121.0653 | 121.0659 | 0.56 | 1 | |
| 28 | Glutaric acid | 2.29 | 131.0344 | 131.0359 | 2.29 | 1 | |
| 29 | 2‐Phenylpropanoic acid | 8.05 | 149.0603 | 149.062 | 1.65 | 1 | |
| 30 | p‐Coumaric acid | 4.92 | 163.0395 | 163.0408 | 1.31 | 1 | |
| 31 | Gallic acid | 1.89 | 169.0137 | 169.0148 | 1.15 | 1 | |
| 32 | Ferulic acid | 6.03 | 193.0501 | 193.0508 | 0.66 | 1 | |
| 33 | Resorcinol | 2.9 | 109.029 | 109.0302 | 1.24 | 1 | |
| 34 | Resorcinol sulfate | 2.87 | 188.9858 | 188.9866 | 0.8 | 1 |
RT, retention time (min).
a)Annotation level according to the Metabolomics Society Initiative.
Annotation level: 1, unambiguously identified metabolites, checked with standard; 2, putatively annotated, based on accurate mass and MS/MS fragments; and 3, putatively characterized.
Figure 1Metabolic pathway of isoflavone metabolites detected in serum after the ingestion of boiled soybean (BS) or Cheonggukjang (CGJ).
Figure 2Overview of t max and t 1/2 (h) for 34 isoflavone metabolites of boiled soybean (BS) or Cheonggukjang (CGJ) in sham and ovariectomized (OVX) mouse groups. The numbers correspond to the metabolite numbers in Table 2.
Figure 3Relative peak area changes of isoflavone metabolites of boiled soybean (BS) and Cheonggukjang (CGJ) in sham and ovariectomized (OVX) mouse groups. The relative peak areas of pooled samples from each group are shown in the heatmap. The relative peak areas are shown with a logarithmic scale. *p < 0.05; **p < 0.01; and ***p < 0.001.
Wilcoxon signed‐rank test comparison of Pmax and area under the curve (AUC) of boiled soybean (BS) and Cheonggukjang (CGJ) treatment in sham and ovariectomized (OVX) mice.
| No. | Group of metabolites | Metabolite |
| AUC (0–24 h, PA mL–1) | ||
|---|---|---|---|---|---|---|
| Sham | OVX | Sham | OVX | |||
| BS‐CGJ | BS‐CGJ | BS‐CGJ | BS‐CGJ | |||
| 1 | Isoflavone | Genistein | – | – | <0.05 | <0.01 |
| 2 | Daidzein | – | – | <0.001 | – | |
| 3 | Glycitein | – | – | – | – | |
| 4 | Phase I (Liver) | 3‐Hydroxygenistein | – | – | – | <0.05 |
| 5 | 6‐Hydroxydaidzein | – | – | – | <0.05 | |
| 6 | Phase II (Liver) | Genistein 4′‐glucuronide | – | <0.001 | – | – |
| 7 | Genistein 7‐glucuronide | – | – | – | – | |
| 8 | Genistein 4′‐sulfate | <0.05 | – | <0.05 | <0.05 | |
| 9 | Genistein 7‐sulfate | – | – | – | – | |
| 10 | Daidzein 7‐glucuronide | – | – | <0.01 | – | |
| 11 | Daidzein 4′‐sulfate | <0.001 | – | <0.01 | – | |
| 12 | Methylgenistein | – | <0.001 | – | – | |
| 13 | Formononetin | – | – | <0.01 | <0.001 | |
| 14 | Gut‐mediated metabolites | Dihydrogenistein | – | – | – | <0.05 |
| 15 | Dihydrogenistein sulfate | – | – | – | <0.05 | |
| 16 | Dihydrodaidzein | – | – | – | <0.05 | |
| 17 | Dihydrodaidzein sulfate | – | – | – | <0.05 | |
| 18 | Equol 7‐glucuronide | – | – | <0.01 | <0.05 | |
| 19 | Equol 4′‐sulfate | <0.01 | <0.001 | <0.05 | – | |
| 20 | 5‐hydroxy equol | – | – | – | <0.05 | |
| 21 | Hippuric acid | – | – | – | – | |
| 22 | 4‐hydroxybenzoic acid | – | – | <0.01 | <0.05 | |
| 23 | 2,6‐Dimethoxy benzoic acid | – | – | – | – | |
| 24 | Caffeic acid | – | – | – | <0.05 | |
| 25 | Methyl caffeic acid | – | – | – | <0.05 | |
| 26 | Fumaric acid | – | – | – | – | |
| 27 | 4‐Ethylphenol | – | – | – | – | |
| 28 | Glutaric acid | – | – | – | <0.05 | |
| 29 | 2‐Phenylpropanoic acid | – | – | – | – | |
| 30 | p‐Coumaric acid | – | – | <0.01 | <0.05 | |
| 31 | Gallic aicd | – | – | – | <0.05 | |
| 32 | Ferulic acid | – | – | – | – | |
| 33 | Resorcinol | – | – | – | – | |
| 34 | Resorcinol sulfate | – | – | – | – | |
a)Metabolites that were significantly increased in the BS‐treated group compared with the CGJ‐treated group.
Figure 4Isoflavone metabolites stimulate alkaline phosphatase (ALP) activity and inhibit bone resorption activity. A) MC3T3‐E1 cells were differentiated for 6 days in medium containing 50 μg mL–1 l‐ascorbic acid, 10 mm β‐glycerophosphate, and 10 nm dexamethasone, and ALP activity was measured. B) Effects of isoflavone metabolites on mineralization of MC3T3‐E1 cells. C) RAW 264.7 cells were treated with 100 ng mL–1 receptor activator of nuclear factor kappa‐B ligand (RANKL) and samples for 5 days without medium change. Bone resorption activity was measured. Values represent the means ± SD (n = 3) of three independent experiments. *p < 0.05; **p < 0.01; and ***p < 0.001 compared to the control group.